GeoVax Labs, Inc.
GOVXHealthcare|Biotechnology|US
$0.16
-0.00 (-0.06%)
DCF Value
$0.17
Tangible Book / Share
$0.39
Cash / Share
$0.69
Clinical Trials (1)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04041674 Evaluating the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of GEO-D02 DNA and MVA/HIV62B With and Without B63521^11 gp120 and IHV01 gp120 Env Proteins in Healthy, HIV-uninfected Adult Participants | HIV Infections | P1 | Withdrawn | — | RCT, Double-blind | GEO-D02 DNA, MVA/HIV62B Vaccine, B63521^11 gp120, IHV01 Protein, Protein Placebo |